India could soon get a lot thinner - at least in theory. On Friday, the patent on semaglutide - the molecule behind Danish drugmaker Novo Nordisk's blockbuster weight-loss drugs Wegovy and Ozempic - expires in the country. This will allow domestic pharmaceutical companies to manufacture cheaper copies or generics, which could significantly reduce costs and increase accessibility for the population.
Investment bank Jefferies has termed this a 'magic-pill moment' for India, predicting the semaglutide market could reach $1 billion domestically with competitive pricing. Analysts anticipate around 50 branded generics to enter the market within months, similar to the rapid rollout seen with sitagliptin when its patent expired.
Currently, India's pharmaceutical industry is valued at approximately $60 billion, with expectations to double by 2030. The industry thrives on generics, making it well-positioned for intense competition over semaglutide, potentially making what was once an expensive drug more widely accessible.
Developed initially for diabetes, drugs like semaglutide have emerged as effective weight-loss solutions by regulating appetite and blood sugar levels. They work by boosting insulin release and delaying stomach emptying, leading to prolonged feelings of fullness. As India's obesity problem grows, these medications could provide essential tools for treatment.
With over 77 million diabetics and substantial obesity rates in the country, the advent of cheaper GLP-1 drugs could revolutionize the treatment landscape. However, there are concerns regarding quality control, potential misuse, and advertising practices that could mislead consumers about the drugs' effectiveness.
Experts caution that while cheaper access to weight-loss medications is a positive development, it must come alongside stringent regulations to ensure the safety and efficacy of these new generics, thus avoiding any negative consequences from poorly manufactured products. As India prepares for this shift in its pharmaceutical landscape, the focus will remain on balancing affordability with quality.
Investment bank Jefferies has termed this a 'magic-pill moment' for India, predicting the semaglutide market could reach $1 billion domestically with competitive pricing. Analysts anticipate around 50 branded generics to enter the market within months, similar to the rapid rollout seen with sitagliptin when its patent expired.
Currently, India's pharmaceutical industry is valued at approximately $60 billion, with expectations to double by 2030. The industry thrives on generics, making it well-positioned for intense competition over semaglutide, potentially making what was once an expensive drug more widely accessible.
Developed initially for diabetes, drugs like semaglutide have emerged as effective weight-loss solutions by regulating appetite and blood sugar levels. They work by boosting insulin release and delaying stomach emptying, leading to prolonged feelings of fullness. As India's obesity problem grows, these medications could provide essential tools for treatment.
With over 77 million diabetics and substantial obesity rates in the country, the advent of cheaper GLP-1 drugs could revolutionize the treatment landscape. However, there are concerns regarding quality control, potential misuse, and advertising practices that could mislead consumers about the drugs' effectiveness.
Experts caution that while cheaper access to weight-loss medications is a positive development, it must come alongside stringent regulations to ensure the safety and efficacy of these new generics, thus avoiding any negative consequences from poorly manufactured products. As India prepares for this shift in its pharmaceutical landscape, the focus will remain on balancing affordability with quality.
